Clinical trial
A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02993731 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2016
- Completion date
- March 31, 2020
- Enrollment
- 1,134 (actual)
- Sites
- 267
Conditions
As the registry lists them; a condition with its own page is linked.